Kornimate/medical-research-clean huggingface dataset:
the effect of blood and blood products transfusion training based on the flipped classroom model on nursing students

Conditions: Self-efficacy

Summary: blood is a living tissue with many vital functions that provide perfusion of organs. therefore, blood transfusion is a tissue transplant and a complicated treatment method that is applied very frequently. many reactions may develop during transfusion due to application errors. in this direction, it is necessary to increase the knowledge and skills of nursing students regarding safe blood transfusion during their undergraduate education. on the other hand, self-efficacy is a more comprehensive concept that includes the concepts of knowledge and skills, and self-efficacy perception is considered important in terms of indicating a level of professional development. it is important to use effective teaching methods to increase the knowledge and skills of students and to support their self-efficacy. the flipped classroom model is a teaching method that has the potential to change teaching and learning for nursing education. in the light of this information, this study was planned to determine the effect of education based on the flipped classroom model on the self-efficacy of senior nursing students regarding blood and blood product transfusion.

the study is a non-drug clinical randomized controlled trial and was conducted between february and june 2024. the universe of the study consisted of senior nursing students of the faculty where the study was conducted. in terms of reliability of the study, control group data will be collected first. criteria for inclusion in the study; being a senior nursing student and being a volunteer.

Eligibility criteria:
inclusion criteria: * being a senior nursing student * nursing students who volunteered to participate in the study exclusion criteria: * there are no exclusion criteria

Keywords: blood transfusion flipped classroom , student
validation and exploration of sleep and mood predictors

Conditions: Sleep Apnea Syndromes; Depression; Lung Diseases; Sleep

Summary: to determine whether objectively recorded sleep durations were mortality risk factors, whether sleep duration could be distinguished from depression as a risk factor in women's health initiative (whi) data, and whether sleep-associated risks were attributable to specific pathophysiologic processes such as sleep apnea, circadian rhythm phase advances, or deficiencies of melatonin, or deficiencies of reproductive steroids. the study was ancillary to the whi.

background: both reported short sleep and reported long sleep are major predictors of excess mortality risk, but the importance of reported sleep duration as a risk factor is not yet known. sleep-related risks are of special interest to the women's health initiative (whi), because insomnia increases among women at menopause, and because whi's hormone replacement therapy (hrt) and dietary modification (dm) may influence sleep. the whi is an exciting opportunity to examine whether risks associated with reported sleep durations can be explained by a selection of intercurrent conditions, but the broad whi design does not control for important potential confounders. explicitly, the broad whi design by itself cannot determine if behaviorally-modifiable objective sleep durations are the primary risk factor. design narrative: this ancillary project supplemented the whi observational study (os) by performing additional examinations on 600 san diego os women. these volunteers underwent home sleep recordings, hormone measurement, and detailed psychiatric interviews. to facilitate distinction of affective and sleep factors in whi outcomes, the types and severity of depression in the os subsample and the validity and reliability of sleep items in questionnaires given to whi women were examined. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
a study of treatment patterns in her2-positive unresectable and advanced gastric/ gastroesophageal junction cancer in china

Conditions: Gastric Cancer; Gastroesophageal Junction Cancer

Summary: this study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for her2-positive gastric cancer/gastroesophageal junction cancer (gc/gejc) patients.

this is a multicenter, non-interventional, retrospective real-world study to analyze the treatment patterns for patients with gc/gejc in the first-line, second-line, and subsequent lines of treatment. the study will also assess different her2 sample types, testing methods, and her2 re-biopsy situations. by evaluating the treatment and testing patterns in clinical practice, this study aims to provide evidence and recommendations for improving the strategies for the treatment and testing of her2-positive gc/gejc patients.

Eligibility criteria:
inclusion criteria * patients with pathologically diagnosed locally advanced unresectable or metastatic gc/gejc (limited to those diagnosed since october 1, 2017) and initiating first-line treatment between january 1, 2018, and march 31, 2023 * patients aged ≥ 18 years at the time of diagnosis with locally advanced unresectable or metastatic gc/gejc; her2-positive status2, determined by either tissue samples from the first biopsy or liquid biopsy samples (if a patient has both tissue and liquid biopsy samples, tissue samples will be the standard). exclusion criteria * patients with other primary malignant tumors * patients enrolled in clinical trials and receiving active anti-cancer therapy after july.1, 2017 (excluding retrospective studies). * patients with critical missing data in medical records or otherwise deemed for inclusion by the investigator

Keywords: gastric cancer gastroesophageal junction cancer her2 real-world
comprehensive multiparametric magnetic resonance imaging after transurethral resection of non muscle-invasive bladder tumor; can it replace second look biopsy? a prospective study

Conditions: Bladder Cancer

Summary: the aim of the study is to prospectively assess the role of mpmri as a non invasive method for assessment of possible residual tumor after initial resection of non muscle invasive bladder tumor.

comprehensive multiparametric (mp) mri which includes t2 weighted imaging, dynamic contrast enhanced (dce) imaging and dwi, was proven to be efficient tool in differentiating benign and malignant bladder lesion. morphological characterization of malignant bladder lesion (mapping/size/morphology/stalk), t stage differentiation and histological grade discrimination. the application of mpmri in nmibc with its added value as non invasive tool for initial staging and after primary resection could be a new helpful method for better diagnosis, risk categorization, refining the indications of second resection and proper determination of adjuvant treatment.

Eligibility criteria:
inclusion criteria: 1. ability to give informed consent. 2. patients with primary or recurrent papillary nmibc. 3. normal cardiac, hematological, and renal functions. exclusion criteria: * 1. patients with history of previous radiotherapy or systemic chemotherapy. 2. patients suffering from immuno-deficiency or other malignancies. 3. patients with high serum creatinine (more than 2 mg/dl). 4. patients with contraindication to mri (claustrophobia-pacemaker- metallic prosthesis).

Keywords: non muscle invasive bladder cancer multiparametric magnetic resonance imaging second resection
integrated discovery and development of innovative tb diagnostics

Conditions: Tuberculosis, Pulmonary

Summary: the long term goal of this project is to provide information critical to the development and use of a low-cost, point-of-care, rapid, simple, and highly accurate diagnostic tool that can help clinicians make a microbiological diagnosis in children who present with signs and symptoms suggestive of tb. specific aim 1: to identify the types of patient samples from which to best detect mtb dna in children with tb. we propose to obtain serial samples of sputum, blood, stool, and gastric and nasopharyngeal secretions from children with symptomatic tb and to use molecular methods to characterize the distribution of mtb in these samples. the results of this study will allow us to identify the most promising sampling strategies for diagnosis of tb in children so that optimization of these easily-accessible samples for detection of mtb nucleic acids can be addressed. specific aim 2: to determine whether cell free mtb dna can be detected in plasma and urine samples of children and adults with tb and to describe the host-related factors that alter the sensitivity of this assay. we propose to test serial urine and plasma samples for mtb dna fragments in two groups: (1) children with symptoms of tb and (2) adults with tb. here, we will optimize sample volume sizes and of state-of-the-art sequencing tools to improve dna recovery and detection. this study will help identify optimal samples and strategies for the non-invasive diagnosis of mtb using urine. secondary aim: to create a bank of archived specimens for (1) optimization of mtb dna purification, extraction, and (2) use in future pediatric tb diagnostic research.


Eligibility criteria:
inclusion criteria for aim 1: children must meet all of the following criteria at the time of enrollment to participate: * age \< 15 years; * presents to a participating health center; * meets the criteria for enrollment of children into tb diagnostic evaluation studies * has a history of contact with an adult with tb disease; and * a guardian provides informed consent for minor to participate and, if age 8 to 14 years, the minor also provides assent. inclusion criteria for aim 2: inclusion criteria for children who participate in aim 2 will be the same as for those for aim 1. adults who participate in aim 2 must meet all of the following criteria at the time of enrollment to participate. * age ≥ 18 years; * presents to a participating health center; * is diagnosed with incident pulmonary tb; * has sputum smear microscopy results; * has not yet initiated tuberculosis treatment; and * is willing to receive a rapid hiv test. exclusion criteria: -

Keywords: pediatric diagnostic cell-free dna molecular tuberculosis
laser therapy versus narrow band ultraviolet b for the treatment of acne vulgaris

Conditions: Skin Diseases

Summary: forty-five participants with facial av were assigned randomly to three groups of fifteen subjects each. each group received various therapies. group a (study group a) had received both nbub and akne-mycin; group b( study group b) had received red lllt and akne-mycin and group c (control group) received only akne-mycin cream. all 45 participants are tested at the initial treatments, after 4 weeks and after 8 weeks by the acne count, the intensity scale and the photographic test.

forty-five patient (18 male and 27 female) were recruited on a referral basis from the department of dermatology at kasr al- aini teaching hospital. firstly, an interview was held with each participant to determine gender, age, skin type, acne severity and medical prescriptions,randomization was performed by selecting numbers from opaque envelopes containing numbers that were chosen by a random number generator, selection was done by an independent person. patients in group (a) received a program of nbub, ( dixwell emly 98 -abrp 64 ,made in france) wavelength 311 to 313nm , in addition to topical aknemycin medications. each treatment lasts one to eight minutes. the treatments were given three times a week. for 8 weeks.participants in-group (b) received a program of r-lllt that was conducted through laser equipment ingaas (630 nm, 10 mw, continuous) (rikta, russia) with fluence 12 j/cm2, two sessions per week for 8 weeks .patients in the three groups were asked to apply topical erythromycin cream 2% (akne-mycin- egypt) two times per day on the entire face from the beginning to the end of the treatment period .evaluation was based on formal counts of active lesions (papule and pustule).facial photographs using a digital camera (panasonic, tokyo, japan). and five-point scale of investigators assessment that reflect lesion count improved percentage.

Eligibility criteria:
inclusion criteria: * ages ranged from 18-35 years. * skin type iii and iv. * mild to moderate facial acne. exclusion criteria: * treatment with oral retinoid within past 1 year. * treatment with other acne treatment within past 3 months. * history of treatment with systemic and topical antibiotics for acne vulgaris within the last 1 month. * treatment with oral isotretinoin within the last 6 months. * participants received radiotherapy or chemotherapy. * any history of photosensitivity. * chemical peels during the previous 4 weeks. * seizures, * pregnancy * use of oral contraceptives. * breastfeeding .
treatment protocol for hemophagocytic lymphohistiocytosis 2004

Conditions: Hemophagocytic Lymphohistiocytosis

Summary: without therapy hlh is often fatal, and often rapidly fatal. the treatment protocol hlh-94 has improved survival markedly as compared to the survival earlier. we now aim to improve survival further.

the most dangerous period after hlh diagnosis is the first 2 months. in hlh-2004 we provide additional therapy during this period as compared to in hlh-94.

Eligibility criteria:
inclusion criteria: * patients who fulfil the diagnostic criteria of hlh. exclusion criteria: * prior cytotoxic or cyclosporin treatment for hlh.

Keywords: hemophagocytic lymphohistiocytosis
pneumoperitoneum management with surgiquest airseal® at low vs. higher pressure

Conditions: Shoulder Pain

Summary: a prospective, randomized, controlled single-center clinical study designed to evaluate physician preference related to the use of the surgiquest airseal® insufflation system (ais) at low vs. higher pressures for the management of pneumoperitoneum. subjects will be randomized in a 1:1 treatment device to control ratio into one of two (2) different study arms: 1. ais with an insufflation pressure target of 9mmhg ±1mmhg; or 2. ais with an insufflation pressure target of 15mmhg ±1mmhg.

the study is designed and powered to demonstrate superiority of the ais at low pressure vs. at higher pressure on a single key effectiveness measure: incidence of shoulder pain. patients will be randomized 1:1 to either ais with an insufflation pressure target of 9mmhg ±1mmhg or to ais with an insufflation target pressure of 15mmhg ±1mmhg. secondary outcome measures include severity of shoulder pain measured using a vas scale and medication use, length of hospital stay, aspects of anesthesia management including end tidal co2 and the frequency of adverse events. these outcomes will be evaluated in a controlled population undergoing laparoscopic surgery.

Eligibility criteria:
inclusion criteria: 1. pediatric subjects (\<21 years of age) 2. \> 20 kg in weight; 3. capable and willing to provide parental informed consent and patient assent; 4. acceptable candidate for laparoscopic surgery; exclusion criteria: 1. active cutaneous infection or inflammation; 2. pre-existing immunodeficiency disorder and/or chronic use of systemic steroids; 3. uncontrolled diabetes mellitus 4. known, significant history of bleeding diathesis, coagulopathy, von willebrand's disease or current platelet count \< 100,000 cells/mm3, baseline inr(international normalized ratio) ≥1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24 hours); 5. severe co-existing morbidities having a life expectancy of less than 30 days; 6. currently involved in any other investigational clinical studies; 7. significant anemia with a hemoglobin level less than 10 g/dl or a hematocrit less than 30%; 8. females who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating; 9. extreme morbid obesity (bmi greater than 45 kg/m2) 10. patients presenting with ascites

Keywords: laparoscopic surgical procedures shoulder pain abdominal pain pediatrics
the influence of anxiety and depression on survival in nasopharyngeal carcinoma patients

Conditions: Nasopharyngeal Carcinoma

Summary: this is a prospective, observational cohort study aimed to explore the influence of anxiety and depression to long term survival in nasopharyngeal carcinoma patients.

nasopharyngeal carcinoma (npc) is endemic in southern china and southeast asia. radiotherapy (rt) and chemotherapy are the mainstays of therapy for npc because these tumors are biologically highly radiosensitive and chemosensitive. anxiety and depression symptoms were common psychological symptoms around the time of cancer diagnosis and were often persistent during cancer treatment. psychological symptoms are associated with prolonged hospital stays, lower quality of life, and worse treatment adherence among patients with cancer. depressive symptoms have been demonstrated to predict early mortality among patients with some kinds of cancer. but among npc patients, the influence of anxiety and depression symptoms to long term survival have not be explored. therefore, this prospective, observational cohort study aimed to explore the influence of anxiety and depression to long term survival in npc patients.

Eligibility criteria:
inclusion criteria: * patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including who ii or iii * age between 18-70 * male and no pregnant female * patient have signed on the informed consent, and well understood the objective and procedure of this study exclusion criteria: * the presence of uncontrolled life-threatening illness * pregnancy or lactation * patient with severe medical condition
an effectiveness, safety, and microbiology study of doripenem in patients with nosocomial (hospital-acquired) pneumonia

Conditions: Pneumonia; Bacterial Pneumonia; Ventilator-Associated Pneumonia; Infections, Nosocomial

Summary: the purpose of this study is to evaluate the effectiveness and safety of doripenem monohydrate in the treatment of patients with nosocomial (hospital-acquired) pneumonia.

nosocomial pneumonia (np) accounts for approximately 15% of all hospital-acquired infections. the incidence of np rises in patients who are on breathing machines. the death rate for np can be as high as 30%. np caused by bacteria, such as pseudomonas aeruginosa, has been associated with an increased death rate compared to other pathogens. prompt use of appropriate antibiotics is essential. compounding the issue of nosocomial infections is the increasing rate to which bacteria develop resistance to antibiotics. this hospital based trial is studying doripenem in patients who have nosocomial pneumonia to see if it is effective against bacteria associated with this serious bacterial infection. the duration of treatment can be anywhere from 8 to 14 days. safety evaluations, such as vital signs and laboratory tests will be performed upon enrollment, after 4 days on therapy, after 9 days on therapy for those on greater than 8 days, at the end of therapy, 7 to 14 days after the end of therapy, and 28 to 35 days after the end of therapy. adverse events will be collected throughout the study. clinical response to doripenem therapy will be assessed 7 to 14 days after the end of therapy and the long-term clinical response to doripenem therapy will be assessed 28 to 35 days after the end of therapy. doripenem iv will be administered for a duration of treatment from 8 to 14 days.

Eligibility criteria:
inclusion criteria: * patients suffering from nosocomial pneumonia or ventilator-associated pneumonia * all patients must be hospitalized throughout the treatment period * patients must have microbiological samples (respiratory secretions) suitable for culture and microscopy exclusion criteria: * known or suspected severe kidney impairment * known or suspected liver dysfunction * treatment with any investigational drug or device within 30 days before enrollment * patients with one or more of the following: cystic fibrosis, lung abscess, active tuberculosis * women who are pregnant or lactating

Keywords: pneumonia lung infection bacterial infection hospital-acquired infection ventilator infection antibiotic therapy
wrist cartilage - high resolution in vivo mr t2 mapping- a feasibility study

Conditions: Osteoarthritis

Summary: purpose:evaluate the feasibility of t2 cartilage mapping on mri of the wrist and correlate with t2 mapping of knee cartilage. study protocol: phase 1. 10 healthy volunteers, phase 2. 10 volunteers with osteoarthritis of the wrist, phase 3. 50 patients for studies for routine mr of the wrist. mri protocol: 3 t unit((signa exite hdx),t1, t2 and t2 mapping sequences on axial and coronal orientation.


Eligibility criteria:
inclusion criteria: * phase 1. age:18-40 * phase 2: no age limit, known oa on pre-existing x-rays * phase 3: no age limit, routine mri of the wrist exclusion criteria: * phase 1, 2: wrist trauma/surgery * all phases: any contraindication for mr: eg metals, claustrophobia, etc.

Keywords: cartilage osteoarthritis t2 mapping mri wrist
a drug interaction study between tocilizumab, methotrexate and simvastatin on patients with rheumatoid arthritis.

Conditions: Rheumatoid Arthritis

Summary: this 2 arm study will investigate the pharmacokinetics of simvastatin and methotrexate in combination with tocilizumab to assess any potential drug interactions. patients will be randomized to receive either tocilizumab (10mg/kg iv infusion on day 8) + methotrexate (10-25mg po /week) or tocilizumab + methotrexate + simvastatin (40mg po on days 1, 15 and 43). blood samples will be taken for analysis at intervals up to day 44. the anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-75 years of age; * rheumatoid arthritis for \>=6 months; * methotrexate for \>=12 weeks prior to day 1 (stable at 10-25mg/week for 8 weeks). exclusion criteria: * history of, or current inflammatory joint disease or rheumatic autoimmune disease other than ra; * concurrent treatment with any dmard other than methotrexate; * prior treatment with tocilizumab.
pharmacokinetics and safety of alks 5461 in healthy subjects and subjects with hepatic impairment and normal hepatic function

Conditions: Hepatic Impairment

Summary: this study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of alks 5461.


Eligibility criteria:
inclusion criteria: for all subjects: * has a body mass index (bmi) of 18.0-35.0 kg/m2 and a total body weight \>50 kg * agrees to use an approved method of contraception for the duration of the study * additional criteria may apply for subjects with hepatic impairment: * has mild, moderate, or severe hepatic impairment * has hepatic dysfunction due to hepatocellular disease * additional criteria may apply exclusion criteria: for all subjects: * has any past history or current finding of a clinically significant observed abnormality, psychiatric or medical condition other than hepatic impairment * has a history of gastrointestinal surgery, excluding appendectomy or cholecystectomy * is pregnant, planning to become pregnant, or lactating * has a history of clinically significant allergy or a hypersensitivity to opioids * additional criteria may apply for subjects with hepatic impairment: * has evidence of hepatocellular carcinoma, acute liver disease, biliary obstruction, severe ascites, severe portal hypertension, surgical systemic shunts, or other clinically relevant liver-related disorder or condition * has received a liver transplant * has had esophageal variceal bleeding in the past 2 months * additional criteria may apply